Wellington Management
Wellington Management focuses on investment management by applying its full resources to meet the needs of institutional clients they serve.
Business Model:
Revenue: $1B
Employees: 501-1,000
Rankings
Detailed Wellington Management Information
Geographic Data
Address: 280 Congress Street
City: Boston
State: MA
Zip: 02210
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
397,658Website Global Rank
133,802Website Monthly Traffic
Twitter Followers
Description
Wellington Management focuses on investment management. The company applies its full resources to meet the needs of the institutional clients they serve. Their investment approaches span the global equity, fixed income, currency, commodity, and alternatives markets. They also offer asset allocation, multi-manager, and specialty approaches. It was founded in 1928 and headquartered in Boston, Massachusetts.
Contact Phone:
+16179515000
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2022 | FalconX | Series D | 0 |
| 4/2015 | Jounce Therapeutics | Series B | 0 |
| 10/2020 | Lordstown Motors | Post-IPO Equity | 500M |
| 12/2021 | JUSPAY | Series C | 60M |
| 2/2014 | nCino | Series B | 11M |
| 8/2018 | Slack | Series H | 427M |
| 7/2017 | WeWork China | Series A | 0 |
| 3/2015 | Zuora | Series F | 0 |
| 12/2019 | Impulse Dynamics | Series D | 0 |
| 4/2014 | Pure Storage | Series F | 225M |
| 1/2022 | CodeSee | Seed | 7M |
| 10/2014 | Fintiv | Series B | 185M |
| 11/2021 | Faire | Series G | 0 |
| 6/2017 | Nightstar Therapeutics | Series C | 45M |
| 6/2021 | Payoneer | PIPE | 300M |
| 1/2022 | Creditas | Series F | 0 |
| 3/2021 | Zenas BioPharma | Series A | - |
| 3/2020 | Nurix Therapeutics | Private Equity Round | 120M |
| 8/2016 | Compass | Series D | 75M |
| 6/2021 | Perella Weinberg Partners | Post-IPO Equity | 125M |
| 9/2018 | Atreca | Series C | 125M |
| 8/2017 | Atreca | Series B | 35M |
| 10/2009 | neoSaej | Venture Round | 1.7M |
| 6/2022 | Kinside | Series A | 0 |
| 4/2014 | Apigee | Venture Round | 0 |
| 8/2021 | Trove | Series D | 77.5M |
| 10/2020 | LianBio | Series A | 0 |
| 2/2015 | Invuity | Equity | 22.9M |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 6/2020 | Freeline | Series C | 80M |
| 11/2017 | HeartFlow | Series E | 0 |
| 2/2021 | Gemini Therapeutics | Post-IPO Equity | 0 |
| 7/2020 | Olema Oncology | Series B | 54M |
| 3/2022 | Span.IO | Series B | 0 |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 6/2017 | Houzz | Series E | 400M |
| 4/2023 | HeartFlow | Series F | 0 |
| 12/2022 | Dataiku | Series F | 200M |
| 11/2014 | Powa | Series C | 80M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 1/2017 | Neon Therapeutics | Series B | 70M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 9/2020 | Novellus | Series C | 57M |
| 7/2022 | Meati Foods | Series C | 0 |
| 8/2020 | PMV Pharmaceuticals | Series D | 70M |
| 6/2021 | Lendbuzz | Series C | 0 |
| 4/2021 | Urban Company | Series F | 188M |
| 5/2014 | Datalogix | Series C | 45M |
| 3/2020 | JUSPAY | Series B | 21.6M |
| 3/2021 | Scribe Therapeutics | Series B | 100M |
| 6/2015 | Cogent Biosciences | Series B | 65M |
| 11/2021 | Chroma Medicine | Series A | 125M |
| 9/2016 | DEFY Media | Series B | 70M |
| 6/2019 | Omada Health | Series D | 73M |
| 11/2017 | Tricida | Series D | 0 |
| 3/2021 | Paidy | Series D | 0 |
| 4/2021 | Swiggy | Series J | 0 |
| 4/2019 | Prove (formerly Payfone) | Series G | 15.1M |
| 2/2016 | Magic Leap | Series C | 793.5M |
| 1/2021 | Affinivax | Series C | 226M |
| 9/2020 | Affirm | Series G | 500M |
| 4/2015 | Rethink Robotics | Series D | 13.4M |
| 9/2022 | RayzeBio | Series D | 160M |
| 1/2015 | Global Blood Therapeutics | Series B | 48M |
| 9/2014 | Adaptimmune | Series A | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 4/2021 | Current | Series D | 220M |
| 10/2021 | BetterUp | Series E | 0 |
| 8/2015 | Payoneer | Series E | 50M |
| 7/2021 | Blackbuck | Series E | 0 |
| 5/2017 | Peloton | Series E | 0 |
| 8/2014 | The Honest Company | Series C | 70M |
| 9/2021 | SpotOn | Series E | 300M |
| 3/2015 | Birst | Series F | 65M |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 5/2015 | MarkLogic | Series F | 102M |
| 9/2021 | Asher Bio | Series B | 0 |
| 7/2000 | SensAble Technologies | Series C | 23M |
| 10/2020 | Gracell Biotechnologies | Series C | 0 |
| 12/2020 | Cityblock Health | Series C | 160M |
| 1/2015 | Moderna Therapeutics | Series E | 0 |
| 4/2019 | Satsuma Pharmaceuticals | Series B | 0 |
| 10/2019 | Current | Series B | 31.2M |
| 8/2020 | Synthego | Series D | 100M |
| 11/2022 | AMP Robotics | Series C | 0 |
| 6/2018 | ezCater | Series D | 100M |
| 5/2023 | Quince | Series B | 0 |
| 4/2021 | Patreon | Series F | 155M |
| 12/2021 | ROKT | Series E | 325M |
| 1/2020 | Generation Bio | Series C | 110M |
| 4/2015 | Warby Parker | Series D | 100M |
| 9/2020 | Attentive | Series D | 230M |
| 1/2022 | Dave | Post-IPO Equity | 0 |
| 12/2014 | Redfin | Series G | 71M |
| 9/2020 | Skillz | Post-IPO Equity | 0 |
| 3/2021 | Cityblock Health | Series C | 192M |
| 8/2014 | Pure Storage | Secondary Market | 60M |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 2/2022 | Synthego | Series E | 0 |
| 6/2020 | Goldfinch Biopharma | Series B | 100M |
| 11/2022 | MBX Biosciences | Series B | 115M |
| 9/2015 | General Assembly | Series D | 70M |
| 9/2020 | Patreon | Series E | 90M |
| 7/2021 | Markforged | Post-IPO Equity | 0 |
| 4/2021 | Greenlight | Series D | 260M |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 3/2023 | Span.IO | Series B | 0 |
| 6/2015 | Airbnb | Series E | 1.5B |
| 10/2014 | Invitae | Series F | 0 |
| 2/2021 | Butterfly Network | Post-IPO Equity | 175M |
| 10/2018 | Coinbase | Series E | 300M |
| 6/2015 | Harry&s;s | Series C | 97.5M |
| 4/2019 | Affirm | Series F | 300M |
| 9/2015 | Rubicon | Series C | 57.1M |
| 6/2021 | Latch | Post-IPO Equity | 190M |
| 8/2014 | Civitas Therapeutics | Series C | 0 |
| 4/2019 | ezCater | Series D | 150M |
| 11/2014 | Nivalis Therapeutics | Venture Round | 30M |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 10/2020 | Scopely | Series E | 340M |
| 6/2021 | Faire | Series F | 260M |
| 6/2015 | TabbedOut | Series C | 21.5M |
| 4/2023 | Clerkie | Series A | 0 |
| 5/2015 | DocuSign | Series F | 0 |
| 8/2015 | Rhythm Metabolic | Series A | 40M |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2023 | Upstream Bio | Series B | 0 |
| 3/2020 | Kymera Therapeutics | Series C | 102M |
| 9/2021 | Arcadia | Series D | 0 |
| 6/2014 | Uber | Series D | 1.4B |
| 10/2017 | Forty Seven | Series B | 75M |
| 8/2014 | Lookout | Series F | 150M |
| 2/2017 | Fuze, an 8x8 company | Series E | 104M |
| 9/2018 | PagerDuty | Series D | 90M |
| 11/2017 | Compass | Series E | 0 |
| 6/2022 | Guild Education | Series F | 0 |
| 5/2021 | Snapdocs | Series D | 150M |
| 6/2020 | Prove (formerly Payfone) | Series H | 98M |
| 8/2018 | Peloton | Series F | 0 |
| 1/2015 | SoFi | Series D | 213M |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 11/2019 | ACV | Series E | 150M |
| 12/2021 | Anchorage Digital | Series D | 0 |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 6/2016 | Mersana Therapeutics | Series C | 33M |
| 2/2021 | Centessa Pharmaceuticals | Series A | 250M |
| 7/2020 | VelosBio | Series B | 137M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 2/2022 | Somatus | Series E | 0 |
| 5/2022 | Arcadia | Series E | 0 |
| 2/2015 | nCino | Series B | 29M |
| 1/2021 | Scorpion Therapeutics | Series B | 162M |
| 11/2014 | Blueprint Medicines | Series C | 50M |
| 4/2021 | Boundless Bio | Series B | 105M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 5/2021 | Nuvalent | Series B | 0 |
| 7/2021 | Strata Oncology | Series C | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 3/2016 | The Trade Desk | Series C | 60M |
| 2/2020 | Swiggy | Series I | 113M |
| 9/2015 | SoFi | Series E | 1B |
| 10/2017 | PolicyBazaar | Series E | 77M |
| 9/2021 | Archaea Energy | Post-IPO Equity | 0 |
| 6/2023 | Caraway | Series A | 0 |
| 1/2016 | ForeScout Technologies | Series G | 80M |
| 7/2022 | Moving Analytics | Series A | 0 |
| 5/2016 | Speakaboos | Series B | 12.5M |
| 3/2015 | Nanigans | Series B | 24M |
| 8/2020 | Dyne Therapeutics | Series B | 115M |
| 8/2013 | Powa | Series A | 76M |
| 1/2021 | Billtrust | Post-IPO Equity | 200M |
| 12/2014 | Coupang | Private Equity Round | 300M |
| 7/2021 | Hyzon Motors | Post-IPO Equity | 0 |
| 1/2022 | Digit Insurance | Venture Round | 70M |
| 4/2014 | New Relic | Private Equity Round | 100M |
| 5/2019 | Away | Series D | 100M |
| 3/2021 | Arrival | Post-IPO Equity | 400M |
| 12/2020 | Creditas | Series E | 255M |
| 4/2021 | Greenlight | Series D | 260M |
| 6/2021 | ironSource | Post-IPO Equity | 0 |
| 8/2014 | Nutanix | Series E | 140M |
| 12/2020 | Porch Group | Post-IPO Equity | 150M |
| 7/2016 | Sprinklr | Series F | 105M |
| 11/2020 | Current | Series C | 131M |
| 10/2014 | WeWork | Series D | 355M |
| 10/2014 | GreenSky | Private Equity Round | 350M |
| 10/2020 | Olema Oncology | Series C | 85M |
| 4/2016 | Kala Pharmaceuticals | Series C | 68M |
| 5/2015 | Series G | 186M | |
| 4/2021 | Scale AI | Series E | 325M |
| 12/2022 | ROKT | Secondary Market | - |
| 7/2021 | Thriveworks | Venture Round | - |
| 9/2014 | Veracode | Series F | 40M |
| 10/2018 | Tanium | Private Equity Round | 200M |
| 8/2022 | SeatGeek | Series E | 238M |
| 12/2017 | Neon Therapeutics | Series B | 36M |
| 2/2022 | Omada Health | Series E | 0 |
| 1/2021 | PPRO | Private Equity Round | 180M |
| 8/2015 | The Honest Company | Series D | 100M |
| 5/2021 | Oxford Nanopore Technologies | Venture Round | 270.8M |
| 12/2019 | FORMA Therapeutics | Series D | 100M |
| 11/2017 | Arcus Biosciences | Series C | 107M |
| 7/2021 | Sundae | Series C | 0 |
| 5/2016 | BEGiN | Series B | 0 |
| 12/2021 | Course Hero | Series C | 380M |
| 3/2015 | Dataminr | Series D | 130M |
| 5/2014 | Malauzai Software | Series C | 6.5M |
| 12/2021 | Olist | Series E | 186M |
| 5/2014 | Spark Therapeutics | Series B | 72.8M |
| 7/2021 | Lucid Motors | Post-IPO Equity | 0 |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 7/2021 | EVgo | Post-IPO Equity | 400M |
| 12/2015 | Allena Pharmaceuticals | Series C | 0 |
| 8/2015 | Klarna | Secondary Market | 80M |
| 6/2020 | Verve Therapeutics | Series A | 63M |
| 9/2022 | flavrs | Seed Round | 0 |
| 4/2000 | Optical Switch | Venture Round | 0 |
| 4/2015 | Voyager Therapeutics | Series B | 0 |
| 4/2015 | Sharecare | Venture Round | 0 |
| 11/2018 | Auris Health | Series E | 0 |
| 4/2015 | Oscar Health | Series C | 145M |
| 7/2017 | Vets First Choice | Private Equity Round | 223M |
| 12/2018 | Swiggy | Series H | 1B |
| 7/2022 | Meati Foods | Series C | 0 |
| 7/2022 | Moving Analytics | Series A | 0 |
| 6/2022 | FalconX | Series D | 0 |
| 6/2022 | Kinside | Series A | 0 |
| 6/2022 | Guild Education | Series F | 0 |
| 5/2022 | Arcadia | Series E | 0 |
| 3/2022 | Span.IO | Series B | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 2/2022 | Somatus | Series E | 0 |
| 2/2022 | Synthego | Series E | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
